NBIX
Neurocrine Biosciences Inc
143.20$
+1.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +3.3% | +0.0% | +14.5% | +5.4% | +0.9% | -8.8% | +20.1% | +15.6% | +1.3% | +1.1% | +17.7% | – | |
| – | -24.1% | -11.8% | +22.7% | -13.0% | +16.3% | -1.1% | +22.8% | +23.9% | +25.7% | -21.6% | +68.1% | – | |
| – | +3.9% | +0.2% | +14.4% | +5.7% | +0.7% | -8.9% | +20.0% | +15.5% | +0.9% | +1.6% | +16.9% | – | |
| – | -3.3% | +15.9% | +19.9% | +2.0% | -4.8% | +41.8% | -7.2% | +2.3% | +3.3% | +14.7% | +10.3% | – | |
| – | +7.2% | +11.1% | -0.5% | -3.2% | +22.8% | -3.9% | +3.5% | +1.9% | +3.5% | +5.5% | +38.1% | – | |
| – | +2.9% | +14.6% | +6.6% | -1.2% | +10.7% | +13.3% | -1.7% | +2.1% | +6.5% | +6.5% | +27.3% | – | |
| – | +6.4% | -33.9% | +46.4% | +26.4% | -22.7% | -83.4% | +516.9% | +64.1% | -11.8% | -11.8% | -17.7% | – | |
| – | +0.0% | +0.0% | +4,418.2% | – | – | – | – | – | – | – | – | – | |
| – | +71.5% | -82.6% | +185.8% | +93.0% | -14.6% | -91.0% | +985.0% | +82.9% | -18.0% | +3.1% | -34.3% | – | |
| – | +55.4% | -117.6% | – | +80.1% | -1.7% | -88.6% | +664.7% | +58.3% | +4.1% | -42.9% | -63.6% | – | |
| – | +77.7% | -70.6% | +49.8% | +99.7% | -20.6% | -92.3% | +1,260.8% | +94.9% | -26.6% | +28.8% | -27.0% | – | |
| – | +67.8% | -45.6% | +39.2% | +23.3% | -5.0% | -82.8% | +432.9% | +79.6% | -21.4% | -17.9% | -1.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.